A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Trial To Assess The Safety And Efficacy Of Certolizumab Pegol (CDP870), Dosed Subcutaneously In Patients With Moderate To Severe Crohn's Disease.
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 12 Nov 2017 Outcomes of a population pharmacokinetic model assessing exposure-response relationship of of certolizumab pegol using pooled data from nine clinical trials of certolizumab pegol induction and maintenance therapy in patients with Crohns disease, including C87005,C87031,C87032, C87037, C87042, C87043,C87047, C87048 and C87085, published in the Alimentary Pharmacology and Therapeutics Journal.
- 10 Jan 2017 New trial record